Despite clinical success, cell and gene therapy pipelines are stunted. The core issue is a broken business model, where therapies are difficult to distribute globally and profitably. A scalable manufacturing platform is the key to enabling profitability, which in turn fuels reinvestment into new therapies.

The initial goal was 3D printing tissue. However, the hydrogel's excellent processability (mixability, pumpability) was also the solution to a major bottleneck in drug discovery: automating 3D cell cultures in high-throughput screening (HTS) systems. This secondary characteristic unlocked a better, more immediate market.

Rather than selling single products, Novonesis designs custom blends or "cocktails" of different enzymes and microbes. This tailor-made approach solves specific customer problems so effectively that it makes the solution highly unique and difficult for competitors to replicate.

Focusing on a single, narrow application limits long-term growth. By designing a scalable platform from the outset, MedTech companies can adapt their core technology to other procedures and markets, ensuring future viability and expansion opportunities.

The Innovative Genomics Institute is tackling rare diseases by creating a standardized platform. By keeping elements like the delivery vehicle and enzyme constant and only changing the guide RNA, they aim to create a repeatable 'bucket trial' process for developing hundreds of cures, not just one-offs.

Animal-derived lab materials, like tissue scaffolds, suffer from massive batch variability. By producing a key structural protein recombinantly, its sequence becomes DNA-coded and consistent, just like a therapeutic drug. This approach transforms a variable, multi-component extract into a defined, single-molecule product, ensuring reproducibility.

Resvita's CTO joined because the company first solved the difficult challenge of delivering proteins to the skin. This created a 'plug-and-play' platform that he calls a 'protein designer's dream.' By abstracting away the delivery problem, the team can focus solely on designing the optimal therapeutic protein for each disease.

The primary advantage of cell-free protein synthesis isn't just speed for early material generation. Its real power lies in facilitating a rapid 'design-build-test' cycle, allowing teams to quickly engineer and validate multiple molecular variants against specific design criteria before committing to a final candidate.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.